Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;13(12):3193-3208.
doi: 10.1007/s13555-023-01062-3. Epub 2023 Nov 17.

Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study

Hao Trong Nguyen  1 , Anh Tuan Vu  2 , Nhi Thi Uyen Pham  3 , Tu Nguyen Anh Tran  3 , Nguyen Nhat Pham  3 , Huong Thi Thanh Bui  2 , Thuyen Thi Pham  2 , Vi Thi Thuy Dinh  2 , Yen Thi Bui  4 , Thao Thi Phuong Vu  3
Affiliations

Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study

Hao Trong Nguyen et al. Dermatol Ther (Heidelb). 2023 Dec.

Abstract

Introduction: Psoriasis is a multi-faceted, immune-mediated inflammatory disease associated with a wide range of comorbidities. Real-world data on treatment patterns, comorbidities, and economic burden in patients with psoriasis are needed for comprehensive patient care in Vietnam.

Methods: A retrospective chart review study was conducted using secondary data extracted from patients' medical records of two hospitals in Vietnam, with the aim of identifying adult patients with a confirmed diagnosis of psoriasis. The index date was defined as the date of first diagnosis between 1 January 2020 and 31 October 2021. Sociodemographic factors, disease characteristics, comorbidities, medication usage, drug survival, and medication costs were analyzed.

Results: A total of 661 patients were identified (mean ± standard deviation [SD] age 43.5 ± 14.8 years). The most prevalent comorbidity was dyslipidemia (49.6% of patients), followed by hypertension (23.4%), and psoriatic arthritis (10.4%). In total, 44% of patients received biologic therapies. Overall, 66.7% and 54.3% of patients receiving biologic and non-biologic therapies, respectively, had ≥ 1 comorbidity. Only 23.2% of patients with psoriasis-related comorbidities stopped therapy with biologics. Biologics had a longer retention time (17.0 months) than non-biologics (6.0 months) in patients with comorbidities. Patients with comorbidities had significantly higher total annual healthcare costs than those without comorbidities (in US dollars: USD901 vs. USD304; p < 0.001), mainly due to the relatively higher costs associated with the use of biologics.

Conclusion: Patients with psoriasis in Vietnam experience a high disease and economic burden due to comorbidities. Evidence from this real-world study supports the need for routine monitoring of and an appropriate treatment course for psoriasis-related comorbidities.

Keywords: Comorbidities; Economic burden; Psoriasis; Retrospective study.

PubMed Disclaimer

Conflict of interest statement

Hao Trong Nguyen has served as an advisory board member and speaker for Novartis, Janssen, and Menarini. Nhi Thi Uyen Pham, Tu Nguyen Anh Tran, and Thao Thi Phuong Vu have served as a speaker for Novartis, Janssen, and Menarini. Huong Thi Thanh Bui, Vi Thi Thuy Dinh have served as a speaker for Novartis. Huong Thi Thanh Bui, Vi Thi Thuy Dinh have served as a speaker for Novartis. Yen Thi Bui was an employee of Novartis Vietnam Co., Ltd at the time of manuscript development. Anh Tuan Vu, Nguyen Nhat Pham, and Thuyen Thi Pham have nothing to disclose.

Figures

Fig. 1
Fig. 1
Boxplots of expenditure in patient groups according to comorbidities relating to psoriasis. a Cost of psoriasis treatments and the total expenditure, b total expenditure regarding comorbidities, c–h cost of psoriasis treatment in patients with comorbidities (c), PsA (d), DM (e), hypertension (f), dyslipidemia (g), and obesity (h). p values were obtained using the Mann–Whitney–Wilcoxon test. Values in boxes above the horizontal line are means. DM Diabetes mellitus, PsA psoriatic arthritis, USD US dollar
See this image and copyright information in PMC

References

    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi: 10.1016/S0140-6736(07)61128-3. - DOI - PubMed
    1. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117. doi: 10.3389/fphar.2020.00117. - DOI - PMC - PubMed
    1. Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatol Treat. 2020;31(7):662–679. doi: 10.1080/09546634.2019.1605142. - DOI - PubMed
    1. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265. doi: 10.1016/j.jaad.2018.06.027. - DOI - PubMed
    1. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152–155. doi: 10.1159/000111512. - DOI - PubMed

LinkOut - more resources